Company / SG&A Expense
Sunshine Biopharma Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$16.5M
FY2025
5-year range
$622.4K / $28.7M
FY2021-FY2025
Trend
+25.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 10 years, ranging from $622,437 in FY2021 to $29M in FY2023.
Based on SEC 10-K filings.
$16M in FY2025 with a 5-year CAGR of +90.8%.
Improved from $29M to $16M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +86.3%
- 5-Year CAGR
- +90.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +90.8%, indicating consistent growth.
- In FY2025, sg&a expense increased 25.6% year-over-year.
- Peak sg&a expense was recorded in FY2023.
- Lowest sg&a expense in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $16.5M | +25.6% |
| FY2024 | $13.1M | -54.3% |
| FY2023 | $28.7M | +1025.1% |
| FY2022 | $2.6M | +309.8% |
| FY2021 | $622.4K | -4.5% |
| FY2020 | $651.7K | -44.0% |
| FY2019 | $1.2M | +35.8% |
| FY2018 | $857.2K | -13.7% |
| FY2017 | $993.1K | +27.0% |
| FY2016 | $782.0K | -55.4% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026